- Japan
- /
- Medical Equipment
- /
- TSE:7730
Mani, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Shareholders of Mani, Inc. (TSE:7730) will be pleased this week, given that the stock price is up 14% to JP¥1,432 following its latest full-year results. Revenues of JP¥30b were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at JP¥52.46, missing estimates by 6.3%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the current consensus from Mani's seven analysts is for revenues of JP¥32.2b in 2026. This would reflect a credible 7.4% increase on its revenue over the past 12 months. Per-share earnings are expected to bounce 28% to JP¥67.24. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥31.8b and earnings per share (EPS) of JP¥65.04 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.
See our latest analysis for Mani
There's been no major changes to the consensus price target of JP¥1,396, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Mani analyst has a price target of JP¥1,735 per share, while the most pessimistic values it at JP¥1,200. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Mani's revenue growth is expected to slow, with the forecast 7.4% annualised growth rate until the end of 2026 being well below the historical 15% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 5.6% per year. So it's pretty clear that, while Mani's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Mani's earnings potential next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that in mind, we wouldn't be too quick to come to a conclusion on Mani. Long-term earnings power is much more important than next year's profits. We have forecasts for Mani going out to 2028, and you can see them free on our platform here.
And what about risks? Every company has them, and we've spotted 1 warning sign for Mani you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:7730
Mani
Engages in the manufacture and supply of surgical and dental instruments in Japan and internationally.
Flawless balance sheet with moderate growth potential.
Market Insights
Community Narratives

